The different ways through which specificity works in orthosteric and allosteric drugs

Current Pharmaceutical Design

Volumn 18, Issue 9, 2012, Pages 1311-1316

  Nussinov, Ruth ^a,b   Tsai, Chung Jung ^a  

^a SAIC FREDERICK INC   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Affinity; Allosteric drug design; Allosteric drug development; Allosteric drug specificity; Allostery; Cellular network; Concentration; Dynamic landscape; Pathways

Indexed keywords

ADENOSINE TRIPHOSPHATE; CINACALCET; GLYCINE RECEPTOR; IFENPRODIL; IMATINIB; MARAVIROC; PROTEIN P53; RNA POLYMERASE II;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CELL ENERGY; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; DNA BINDING; DRUG BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORTHOSTERISM; PRIORITY JOURNAL; PROTEIN CONFORMATION; REGULATORY DNA SEQUENCE; TRANSCRIPTION INITIATION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS;

EID: 84857759143     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436377     Document Type: Article

References (58)

1. Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nature Reviews Drug Discovery 2010; 9: 690-701.
2. Wood MR, Hopkins CR, Brogan JT, Conn PJ, Lindsley CW. Molecular Switches on mGluR Allosteric Ligands That Modulate Modes of Pharmacology. Biochemistry 2011; 50: 2403-10.
3. Digby GJ, Conn PJ, Lindsley CW. Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. Current Opinion in Drug Discovery & Development 2010; 13: 587-94.
4. Mohr K, Trankle C, Kostenis E, Barocelli E, De Amici M,Holzgrabe U. Rational design of dualsteric GPCR ligands: quests and promise. British Journal of Pharmacology 2010; 159: 997-1008.
5. Kenakin TP. Ligand Detection in the Allosteric World. Journal of Biomolecular Screening 2010; 15: 119-30.
6. Yevenes GE, Zeilhofer HU. Allosteric modulation of glycine receptors. British Journal of Pharmacology 2011; 164: 224-36.
7. Peracchi A, Mozzarelli A. Exploring and exploiting allostery: Models, evolution, and drug targeting. Biochimica Et Biophysica Acta-Proteins and Proteomics 2011; 1814: 922-33.
8. Hammond AS, Rodriguez AL, Townsend SD, et al. Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology. Acs Chemical Neuroscience 2010; 1: 702-16.
9. Kenakin T, Miller LJ. Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery. Pharmacological Reviews 2010; 62: 265-304.
10. Kenakin TP. '7TM Receptor Allostery: Putting Numbers to Shapeshifting Proteins. Trends in Pharmacological Sciences 2009; 30: 460-9.
11. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Reviews Drug Discovery 2009; 8: 41-54.
12. Kenakin T, Christopoulos A. Analytical pharmacology: the impact of numbers on pharmacology. Trends in Pharmacological Sciences 2011; 32: 189-96.
13. Dowling RJO, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochimica Et Biophysica Acta-Proteins and Proteomics 2010; 1804: 433-9.
14. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Current Opinion in Cell Biology 2010; 22: 169-76.
15. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition. Molecular Cell 2010; 38: 768-74.
16. Tsai CJ, Kumar S, Ma BY, Nussinov R. Folding funnels, binding funnels, and protein function. Protein Science 1999; 8: 1181-90.
17. Gunasekaran K, Ma BY, Nussinov R. Is allostery an intrinsic property of all dynamic proteins? Proteins-Structure Function and Bioinformatics 2004; 57: 433-43.
18. Tsai CJ, Ma BY, Nussinov R. Folding and binding cascades: Shifts in energy landscapes. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 9970-2.
19. Kumar S, Ma BY, Tsai CJ, Sinha N, Nussinov R. Folding and binding cascades: Dynamic landscapes and population shifts. Protein Science 2000; 9: 10-9.
20. Tsai CJ, Del Sol A, Nussinov R. Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. Molecular Biosystems 2009; 5: 207-16.
21. Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nature Chemical Biology 2009; 5: 789-96.
22. Dill KA. Polymer principles and protein folding. Protein Science 1999; 8: 1166-80.
23. Frauenfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. Science 1991; 254: 1598-603.
24. Del Sol A, Tsai CJ, Ma BY, Nussinov R. The Origin of Allosteric Functional Modulation: Multiple Pre-existing Pathways. Structure 2009; 17: 1042-50.
25. Chung SK, Vanbellinghen JF, et al. Pathophysiological Mechanisms of Dominant and Recessive GLRA1 Mutations in Hyperekplexia. Journal of Neuroscience 2010; 30: 9612-20.
26. Hibbs RE, Gouaux E. Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature 2011; 474: 54-U80.
27. Hilf RJC, Dutzler R. Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel. Nature 2009; 457: 115-22.
28. Pless SA, Dibas MI, Lester HA, Lynch JW. Conformational variability of the glycine receptor M2 domain in response to activation by different agonists. Journal of Biological Chemistry 2007; 282: 36057-67.
29. Sadovsky E, Yifrach O. Principles underlying energetic coupling along an allosteric communication trajectory of a voltage-activated K+ channel. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 19813-8.
30. Azaria R, Irit O, Ben-Abu Y, Yifrach O. Probing the Transition State of the Allosteric Pathway of the Shaker Kv Channel Pore by Linear Free-Energy Relations. Journal of Molecular Biology 2010; 403: 167-73.
31. Pan YP, Tsai CJ, Ma BY, Nussinov R. Mechanisms of transcription factor selectivity. Trends in Genetics 2010; 26: 75-83.
32. Georges AB, Benayoun BA, Caburet S, Veitia RA. Generic binding sites, generic DNA-binding domains: where does specific promoter recognition come from? FASEB Journal 2010; 24: 346-56.
33. [Nussinov R, Tsai CJ, Csermely P. Allo-network drugs: harnessing allostery in cellular networks. Trends pharmacological Sci 2011: in press.
34. [Meyer KD, Lin SC, Bernecky C, Gao YF, Taatjes DJ. p53 activates transcription by directing structural shifts in Mediator. Nature Structural & Molecular Biology 2010; 17: 753-U131.
35. Taatjes DJ, Naar AM, Andel F, Nogales E, Tjian R. Structure, function, and activator-induced conformations of the CRSP coactivator. Science 2002; 295: 1058-62.
36. Asturias FJ. RNA polymerase II structure, and organization of the preinitiation complex. Current Opinion in Structural Biology 2004; 14: 121-9.
37. Davis JA, Takagi Y, Kornberg RD, Asturias FJ. Structure of the yeast RNA polymerase II holoenzyme: Mediator conformation and polymerase interaction. Molecular Cell 2002; 10: 409-15.
38. Jimenez GS, Nister M, Stommel JM, et al. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nature Genetics 2000; 26: 37-43.
39. Lin JY, Chen JD, Elenbaas B, Levine AJ. Several hydrophobic amino-acids in the P53 amino-terminal domain are required for transcriptional activation, binding to MDM-2 and the adenovirus-5 E1B 55-KD protein. Genes & Development 1994; 8: 1235-46.
40. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discovery Today 2007; 12: 622-33.
41. Shipe WD, Wolkenberg SE, Williams DL, Lindsley CW. Recent advances in positive allosteric modulators of metabotropic glutamate receptors. Current Opinion in Drug Discovery & Development 2005; 8: 449-57.
42. May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. In: ed.^eds., Annual Review of Pharmacology and Toxicology 2007; pp. 1-51.
43. Lewis JA, Lebois EP, Lindsley CW. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Current Opinion in Chemical Biology 2008; 12: 269-80.
44. Christopoulos A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nature Reviews Drug Discovery 2002; 1: 198-210.
45. Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nature Biotechnology 2010; 28: 63-U93.
46. Karakas E, Simorowski N, Furukawa H. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Nature 2011; 475: 249-U170.
47. Ma B, Tsai C-J, Haliloglu T, Nussinov R. Dynamic Allostery: Linkers Are Not Merely Flexible. Structure 2011; 19: 907-17.
48. Yan S, Appleby T, Larson G, et al. Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: Convergence of structure-based drug design and X-ray crystallographic study. Bioorganic & Medicinal Chemistry Letters 2007; 17: 1991-5.
49. Seo S, Henry JT, Lewis AH, Wang N, Levandoski MM. The Positive Allosteric Modulator Morantel Binds at Noncanonical Subunit Interfaces of Neuronal Nicotinic Acetylcholine Receptors. J Neuroscience 2009; 29: 8734-42.
50. Wu TY, Smith CM, Sine SM, Levandoski MM. Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors. Molecular Pharmacology 2008; 74: 466-75.
51. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Structural Biology 2002; 9: 268-72.
52. Gao ZG, Jacobson KA. Keynote review: Allosterism in membrane receptors. Drug Discovery Today 2006; 11: 191-202.
53. Liu J, Nussinov R. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 901-6.
54. Saldanha SA, Kaler G, Cottam HB, Abagyan R, Taylor SS. Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitiveligands targeting protein kinase A. Analytical Chemistry 2006; 78: 8265-72.
55. Castoreno AB, Eggert US. Small Molecule Probes of Cellular Pathways and Networks. Acs Chemical Biology 2011; 6: 86-94.
56. Van Regenmortel MHV. Molecular recognition in the post-reductionist era. Journal of Molecular Recognition 1999; 12: 1-2.
57. Kar G, Keskin O, Gursoy A, Nussinov R. Allostery and population shift in drug discovery. Current Opinion in Pharmacology 2010; 10: 715-22.
58. [R. Allosteric modulators can restore function in an amino acid neurotransmitter receptor by slightly altering intra-molecular communication pathways. Br J Pharmacol 2012; doi: 10.1111/j.1476-5381.2011.01793.x. PMID: 22122331.